Literature DB >> 10584987

Progesterone directly and indirectly affects perforin expression in cytolytic cells.

G Laskarin1, N Strbo, V Sotosek, D Rukavina, Z Faust, J Szekeres-Bartho, E R Podack.   

Abstract

PROBLEM: Decidual lymphocytes (DL) expressing the cytolytic molecule perforin represent approximately 55% of DL in the first trimester of human pregnancy. Progesterone dominates this phase of pregnancy and controls the production of uterine cytokines and growth factors. The aim of this study was to investigate the role of progesterone and progesterone-induced blocking factor (PIBF) on perforin expression in DL and peripheral blood lymphocytes (PBL). METHOD OF STUDY: Perforin expression was analyzed in PBL and DL incubated either in culture medium or with decidual adherent cells (DAC) and peripheral blood adherent cells (PBAC) and their supernatants with or without progesterone or PIBF. Perforin was detected by flow cytometry in PB and in decidual first trimester pregnancy lymphocytes.
RESULTS: Progesterone in high concentrations directly affects perforin expression in DL but not in PBL. Progesterone in a concentration dependent manner indirectly blocks perforin expression in DL and PBL cultured with adherent cells or their supernatants. PIBF blocked upregulation of perforin expression of DL cultured with DAC, but none of those cultured with PBAC. Similarly, PIBF was inefficient when PBL or DL were cultured with PBAC.
CONCLUSION: Progesterone present in a high concentration locally at the maternal-fetal interface modulates perforin expression in the first trimester pregnancy DL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584987     DOI: 10.1111/j.1600-0897.1999.tb00107.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  17 in total

Review 1.  Sex-associated hormones and immunity to protozoan parasites.

Authors:  C W Roberts; W Walker; J Alexander
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

Review 2.  The Role of Progesterone in Feto-Maternal Immunological Cross Talk.

Authors:  Julia Szekeres-Bartho
Journal:  Med Princ Pract       Date:  2018-06-27       Impact factor: 1.927

3.  Pregnancy-associated cytotoxic lymphoma: a report of 4 cases.

Authors:  M Kato; K Ichimura; Y Hayami; S Iida; A Wakita; R Ueda; S Nakamura
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

Review 4.  Contraceptive methods and risk of HIV acquisition or female-to-male transmission.

Authors:  Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

Review 5.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

6.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

Review 7.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

8.  Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Authors:  Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel
Journal:  Endocrinology       Date:  2013-01-25       Impact factor: 4.736

Review 9.  Inflammation, leukocytes and menstruation.

Authors:  Jemma Evans; Lois A Salamonsen
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

Review 10.  Hormonal contraception and HIV disease progression.

Authors:  Elizabeth Stringer; Erik Antonsen
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.